These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 18245484)

  • 1. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
    Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
    Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
    Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
    Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
    Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
    Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
    Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
    Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
    Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
    Evans AH; Pancholi S; Farmer I; Thornhill A; Evans DB; Johnston SR; Dowsett M; Martin LA
    Br J Cancer; 2010 Apr; 102(8):1235-43. PubMed ID: 20386540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
    Yoshimaru T; Komatsu M; Miyoshi Y; Honda J; Sasa M; Katagiri T
    Cancer Sci; 2015 May; 106(5):550-8. PubMed ID: 25736224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
    Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.